Illinois Municipal Retirement Fund Has $6.89 Million Holdings in Jazz Pharmaceuticals PLC $JAZZ

Illinois Municipal Retirement Fund grew its position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 7.8% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 52,235 shares of the specialty pharmaceutical company’s stock after buying an additional 3,778 shares during the quarter. Illinois Municipal Retirement Fund owned approximately 0.09% of Jazz Pharmaceuticals worth $6,885,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in the company. LSV Asset Management raised its position in Jazz Pharmaceuticals by 3.6% during the second quarter. LSV Asset Management now owns 2,553,742 shares of the specialty pharmaceutical company’s stock valued at $271,003,000 after acquiring an additional 87,576 shares in the last quarter. Ameriprise Financial Inc. increased its stake in shares of Jazz Pharmaceuticals by 11.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,867,399 shares of the specialty pharmaceutical company’s stock worth $198,159,000 after purchasing an additional 191,637 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Jazz Pharmaceuticals by 3.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,721,294 shares of the specialty pharmaceutical company’s stock worth $182,664,000 after purchasing an additional 59,252 shares during the last quarter. Vestal Point Capital LP bought a new position in shares of Jazz Pharmaceuticals during the 2nd quarter valued at $127,344,000. Finally, Geode Capital Management LLC lifted its stake in shares of Jazz Pharmaceuticals by 1.5% in the 2nd quarter. Geode Capital Management LLC now owns 1,171,755 shares of the specialty pharmaceutical company’s stock valued at $124,366,000 after purchasing an additional 16,757 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

JAZZ opened at $166.31 on Friday. The firm has a market capitalization of $10.10 billion, a P/E ratio of -27.40, a price-to-earnings-growth ratio of 0.89 and a beta of 0.26. The stock’s 50 day moving average price is $167.60 and its two-hundred day moving average price is $147.00. The company has a quick ratio of 1.44, a current ratio of 1.65 and a debt-to-equity ratio of 1.09. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $182.99.

Wall Street Analyst Weigh In

Several research firms have commented on JAZZ. Piper Sandler reissued an “overweight” rating and set a $219.00 target price (up from $147.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, December 10th. Wells Fargo & Company upped their price target on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 18th. Needham & Company LLC raised their price objective on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday, January 12th. UBS Group restated a “neutral” rating and issued a $188.00 target price (up from $163.00) on shares of Jazz Pharmaceuticals in a report on Monday, November 24th. Finally, Royal Bank Of Canada set a $194.00 target price on Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research report on Monday, November 17th. Fourteen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $205.67.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 77,500 shares of the company’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $177.81, for a total transaction of $13,780,275.00. Following the completion of the transaction, the director directly owned 393,332 shares in the company, valued at $69,938,362.92. This represents a 16.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Rick E. Winningham sold 5,500 shares of the firm’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $180.86, for a total transaction of $994,730.00. Following the completion of the sale, the director owned 8,893 shares in the company, valued at $1,608,387.98. This represents a 38.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 123,791 shares of company stock valued at $21,991,850 in the last three months. 4.30% of the stock is owned by insiders.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.